GSK for You

Learn more about the test for hypersensitivity

GlaxoSmithKline wants to help your patients to get the drugs they need, even if they don't take our medicines. To learn more about how your patients can save on medicines and GlaxoSmithKline's available drug savings programs, call us toll-free Monday through Friday at 1-866-GSK-FOR-U (1-866-475-3678) between 8:00 am and 8:00 pm Eastern Time, or contact us online.

GlaxoSmithKline has a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better, and live longer. This mission gives us the purpose to develop medicines that help millions of people around the world.
But being a leader brings responsibility. We know that access to medicines is an important issue in this country, because many people don't have prescription drug coverage. In response, GlaxoSmithKline has developed a number of patient assistance programs and discount cards to provide prescription drug help to eligible patients who take our medicines.

GSK assistance programs

Our patient assistance programs provide prescription medicines to eligible low-income, uninsured patients free or at very low cost. GlaxoSmithKline operates several programs, including:

Commitment to Access, which covers cancer treatments
Bridges to Access, which covers other medicines for outpatients
GSK Access, which provides free GlaxoSmithKline medicines to people enrolled in a Medicare drug plan who meet program requirements

GlaxoSmithKline was the first pharmaceutical company in the US to offer a card providing prescription drug help to low-income seniors and disabled people. In 2002, GlaxoSmithKline and six other pharmaceutical companies established the Together Rx card, which provided participating companies' discounts on over 100 prescription medicines to low-income senior citizens who are eligible for Medicare.

Today, we're committed to improving the quality of human life and contributing to a better future for all. That's why we're working to help people who need prescription drug help. Meet members of the GlaxoSmithKline team who are helping callers every day with their prescription drug coverage questions and concerns. To learn more about GlaxoSmithKline, visit our company Web site.

Indication and Usage

EPZICOM, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection. EPZICOM is one of multiple products containing abacavir

Before starting EPZICOM, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir. In one controlled study, more patients taking abacavir 600 mg once daily had severe hypersensitivity reactions compared to patients taking abacavir 300 mg twice daily

It is not recommended that EPZICOM be used as a component of a triple-nucleoside regimen

Important Safety Information

EPZICOM contains abacavir sulfate, which has been associated with serious and sometimes fatal hypersensitivity reactions. Hypersensitivity to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups: (1) fever, (2) rash, (3) gastrointestinal (including nausea, vomiting, diarrhea, or abdominal pain), (4) constitutional (including generalized malaise, fatigue, or achiness), and (5) respiratory (including dyspnea, cough, or pharyngitis). Discontinue EPZICOM as soon as a hypersensitivity reaction is suspected. Permanently discontinue EPZICOM if hypersensitivity cannot be ruled out, even when other diagnoses are possible
Following a hypersensitivity reaction to abacavir, NEVER restart EPZICOM or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death
Reintroduction of EPZICOM or any other abacavir-containing product, even in patients who have no identified history or unrecognized symptoms of hypersensitivity to abacavir therapy, can result in serious or fatal hypersensitivity reactions. Such reactions can occur within hours
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir, lamivudine, and other antiretrovirals
EPZICOM Tablets are contraindicated in patients with hepatic impairment
Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV and have discontinued lamivudine, which is one component of EPZICOM. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue EPZICOM and are coinfected with HIV and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted
Hepatic decompensation (some fatal) has occurred in HIV/HCV coinfected patients receiving combination antiretroviral therapy for HIV and interferon with or without ribavirin. Patients receiving interferon with or without ribavirin and EPZICOM should be closely monitored for treatment-associated toxicities, especially hepatic decompensation. Discontinuation of EPZICOM should be considered as medically appropriate
Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including EPZICOM. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment
Redistribution/accumulation of body fat has been observed in patients receiving antiretroviral therapy. The causal relationship, mechanism, and long-term consequences of these events are currently unknown
In one study of therapy-naïve patients (CNA 30021), the most common adverse events (grade 2-4) reported with abacavir and lamivudine dosed once daily were hypersensitivity (9%), insomnia (7%), depression (7%), headache/migraine (7%), fatigue (6%), dizziness (6%), nausea (5%), diarrhea (5%), rash (5%), pyrexia (5%), abdominal pain (4%), abnormal dreams (4%), and anxiety (3%)